Dynamical Regulation Analysis Identifies Molecular Mechanisms of Fuzheng-Huayu Formula against Hepatitis B-Caused Liver Cirrhosis

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Chen, Qi Long ^a   Lu, Yi Yu ^a   Peng, Jing Hua ^a   Dong, Shu ^a   Wei, Bin ^a   Song, Ya Nan ^a   Zhou, Qian Mei ^a   Zhang, Hui ^a   Liu, Ping ^a   Su, Shi Bing ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FUZHENG HUAYU FORMULA; HERBACEOUS AGENT; MICRORNA; PROTEIN P53; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHINESE MEDICINE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA ISOLATION; SIGNAL TRANSDUCTION; TABLET;

EID: 84937022353     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/238495     Document Type: Article

References (33)

1. A. Hsu, C.-L. Lai, and M.-F. Yuen, "Update on the risk of hepatocellular carcinoma in chronic hepatitis B virus infection, " Current Hepatitis Reports, vol. 10, no. 2, pp. 106-111, 2011.
2. F. E. de Jongh, H. L. A. Janssen, R. A. de Man, W. C. J. Hop, S. W. Schalm, and M. van Blankenstein, "Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver, " Gastroenterology, vol. 103, no. 5, pp. 1630-1635, 1992.
3. T. Yang, D.-P. Shen, Q.-L. Wang, Y.-Y. Tao, and C.-H. Liu, "Investigation of the absorbed and metabolized components of Danshen from Fuzheng Huayu recipe and study on the anti-hepatic fibrosis effects of these components, " Journal of Ethnopharmacology, vol. 148, no. 2, pp. 691-700, 2013.
4. Y.-H. Jia, R.-Q. Wang, H.-M. Mi et al., "Fuzheng Huayu recipe prevents nutritional fibrosing steatohepatitis in mice, " Lipids in Health and Disease, vol. 11, article 45, 2012.
5. Q.-L. Wang, Y.-Y. Tao, L. Shen, H.-Y. Cui, and C.-H. Liu, "Chinese herbal medicine fuzheng huayu recipe inhibits liver fibrosis bymediating the transforming growth factor-β1/smads signaling pathway, " Journal of Chinese Integrative Medicine, vol. 10, no. 5, pp. 561-568, 2012.
6. A. Esquela-Kerscher and F. J. Slack, "Oncomirs - microRNAs with a role in cancer, " Nature Reviews Cancer, vol. 6, no. 4, pp. 259-269, 2006.
7. D. P. Bartel, "MicroRNAs: target recognition and regulatory functions, " Cell, vol. 136, no. 2, pp. 215-233, 2009.
8. J. Hou, L. Lin, W. Zhou et al., "Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma, " Cancer Cell, vol. 19, no. 2, pp. 232-243, 2011.
9. J. J. Forman, A. Legesse-Miller, and H. A. Coller, "A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 39, pp. 14879-14884, 2008.
10. J. R. Lytle, T. A. Yario, and J. A. Steitz, "Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5 UTR as in the 3 UTR, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 23, pp. 9667-9672, 2007.
11. D. Baek, J. Villén, C. Shin, F. D. Camargo, S. P. Gygi, and D. P. Bartel, "The impact of microRNAs on protein output, " Nature, vol. 455, no. 7209, pp. 64-71, 2008.
12. P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., "Circulating microRNAs as stable blood-based markers for cancer detection, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10513-10518, 2008.
13. M. G. Schrauder, R. Strick, R. Schulz-Wendtland et al., "Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection, " PLoS ONE, vol. 7, no. 1, Article ID e29770, 2012.
14. H. Zhuang, "Guideline on prevention and treatment of chronic hepatitis B in China (2005), " Chinese Medical Journal, vol. 120, no. 24, pp. 2159-2173, 2007.
15. T. Vergoulis, I. S. Vlachos, P. Alexiou et al., "TarBase 6.0: capturing the exponential growth of miRNAtargetswith experimental support, " Nucleic Acids Research, vol. 40, no. 1, pp.D222-D229, 2012.
16. F. Xiao, Z. Zuo, G. Cai, S. Kang, X.Gao, and T. Li, "miRecords: an integrated resource for microRNA-target interactions, " Nucleic Acids Research, vol. 37, no. 1, pp.D105-D110, 2009.
17. S.-D. Hsu, F.-M. Lin, W.-Y. Wu et al., "MiRTarBase: a database curates experimentally validated microRNA-target interactions, " Nucleic Acids Research, vol. 39, supplement 1, pp. D163-D169, 2011.
18. D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, " Nature Protocols, vol. 4, no. 1, pp. 44-57, 2009.
19. D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists, " Nucleic Acids Research, vol. 37, no. 1, pp. 1-13, 2009.
20. Y.Guo, Y. Feng, N. S. Trivedi, and S.Huang, "Medusa structure of the gene regulatory network: dominance of transcription factors in cancer subtype classification, " Experimental Biology and Medicine, vol. 236, no. 5, pp. 628-636, 2011.
21. T. Nepusz, H. Yu, and A. Paccanaro, "Detecting overlapping protein complexes in protein-protein interaction networks, " Nature Methods, vol. 9, no. 5, pp. 471-472, 2012.
22. S. Zheng, W. P. Tansey, S. W. Hiebert, and Z. Zhao, "Integrative network analysis identifies key genes and pathways in the progression of hepatitis C virus induced hepatocellular carcinoma, " BMC Medical Genomics, vol. 4, article 62, 2011.
23. L.Chen, R. Liu, Z.-P.Liu, M.Li, andK.Aihara, "Detecting earlywarning signals for sudden deterioration of complex diseases by dynamical network biomarkers, " Scientific Reports, vol. 2, article 342, 2012.
24. J. A. Miller, S. Horvath, and D. H. Geschwind, "Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 28, pp. 12698-12703, 2010.
25. D. He, Z. P. Liu, M. Honda, S. Kaneko, and L. Chen, "Coexpression network analysis in chronic hepatitis B and C hepatic lesions reveals distinct patterns of disease progression to hepatocellular carcinoma, " Journal of Molecular Cell Biology, vol. 4, no. 3, pp. 140-152, 2012.
26. A. Spaziani, A. Alisi, D. Sanna, and C. Balsano, "Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1, " The Journal of Biological Chemistry, vol. 281, no. 16, pp. 10983-10989, 2006.
27. A. H. Stegh, "Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils, " Expert Opinion on Therapeutic Targets, vol. 16, no. 1, pp. 67-83, 2012.
28. I. Fabregat, J. Fernando, J. Mainez, and P. Sancho, "TGF-Beta signaling in cancer treatment, " Current Pharmaceutical Design, vol. 20, no. 17, pp. 2934-2947, 2014.
29. L. Zhang, F. Zhou, A. Garcia deVinuesa, and et al, "TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis, " Molecular Cell, vol. 51, no. 5, pp. 559-572, 2013.
30. A. Saito, H. I. Suzuki, M. Horie et al., "An integrated expression profiling reveals target genes of TGF-beta and TNF-alpha possibly mediated by microRNAs in lung cancer cells, " PLoS ONE, vol. 8, no. 2, Article ID e56587, 2013.
31. S. Lv, J. Qin, R. Yi et al., "Crkl efficiently mediates cell proliferation, migration, and invasion induced by TGF-β pathway in glioblastoma, " Journal of Molecular Neuroscience, vol. 51, no. 3, pp. 1046-1051, 2013.
32. X.Mu, S. Lin, J. Yang et al., "TGF-β signaling is often attenuated duringHepatotumorigenesis, but is retained for themalignancy of hepatocellular carcinoma cells, " PLoS ONE, vol. 8, no. 5, Article ID e63436, 2013.
33. S. Dooley and P. ten Dijke, "TGF-β in progression of liver disease, " Cell and Tissue Research, vol. 347, no. 1, pp. 245-256, 2012.